"... it seems that the DSMB and Clinical Steering Committee are in discussions to potentially delay the futility analysis until some yet to be announced point between 50% and 75% of events."

They are? Sorry, that piece of information went right past me. Where did we learn that? 

Worrisome, as in maybe it is looking like they won't see the results they want in the first 125, so they want to give it one more shot? Which could also explain the delay on the other trial - if bad news were expected. 

But then, they are not supposed to have information on how things are going either, are they?

So it shouldn't be based on bad progress. 

Can't be based on good news though, since early halt due to clear benefit would not seem to be in the cards if this is the case.

Hoping the bad feeling this statement gave me is unfounded.